Scandinavian Biopharma extends its agreement with USAMMDA and obtains additional financial support
In 2020, Scandinavian Biopharma entered into an agreement with the United States Army Medical Materiel Development Activity (USAMMDA) to fund manufacturing and development activities for its ETEC diarrhoea vaccine, ETVAX®. The agreement has now been extended, providing additional financial support.
The objective of USAMMDA’s financial support is to accelerate the development and approval of the vaccine in the United States and to provide its personnel stationed overseas with a registered, safe and effective vaccine against ETEC, which is the most common cause of diarrhoea in travellers to subtropical/tropical regions.
“We are very proud to have received additional funding from USAMMDA for the development of our world-leading ETEC vaccine candidate. This is a confirmation that we have a very promising candidate and a well-developed plan for our remaining development program”, says Björn Sjöstrand, CEO of Scandinavian Biopharma.
